Intervenciones fallidas ponen en riesgo el acceso a medicamentos de 29 millones de colombianos, alerta Afidro
El 75% de las EAPB intervenidas tiene desempeño medio-bajo sin mejoras financieras. Foto: iStock
TL;DR
- Afidro expresses concern over a government audit showing structural deterioration in health entities managed by the National Health Superintendence between 2019 and 2024.
- The audit reveals 75% of intervened Health Benefit Plan Administrators (EAPB) have a 'medium-low' performance with no significant financial sustainability, impacting 29.25 million affiliates (58% of the insured population).
- The risk of a healthcare system crisis has increased, projected to reach 60.4% by 2026, affecting access to necessary medications, diagnostics, and treatments for chronic and high-cost conditions.
- A pharmaceutical manager's decision to suspend services for Nueva EPS is seen as a symptom of operational decline, highlighting severe payment capacity limitations in intervened entities.
- Intervened EAPBs have accumulated debts of $9.3 trillion with the provider network, while administrative expenses exceed 50% of resources in some liquidation processes.
- Past-due accounts have increased by 70%, limiting operations for pharmaceutical supply chain providers and operators.
- The audit found only 6.07% recovery of accounts receivable from liquidated entities, and despite high plan compliance, liquidated entities pay only 35%-40% of their debts.
- There are $770 billion in unpaid debts to State Social Enterprises, reducing their operations and capacity, especially in regions with predominantly public networks.
- Afidro urges the government to implement urgent financial solutions, define the UPC appropriately, and ensure an orderly transition of services to new operators without interrupting patient access to treatments.